Samuel Aparicio MB, BCH, PhD, FRCPath, FRSC

Chief Scientific Officer

Dr. Aparicio graduated in medical and natural sciences from Cambridge University (UK) and clinical medicine from Oxford University (UK). He trained in internal medicine and anatomic pathology. From 2000-2005, Dr. Aparicio was a senior investigator in the Department of Oncology, Cambridge. He co-founded (1999) the UK and Singapore-based biotech company Paradigm Therapeutics (now Takeda Cambridge), where he was Director of Science until 2004. Dr. Aparicio is currently the Nan and Lorraine Robertson Chair of Breast Cancer Research, based at UBC/BC Cancer Agency, Vancouver, Canada, and a Canada Research Chair in Molecular Oncology. His work encompasses the fields of cancer evolution, single-cell genomics, mouse genetic models, high throughput screens, and translational breast cancer research.

Select Publications

Clonal Decomposition and DNA Replication States Defined by Scaled Single-Cell Genome Sequencing

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer

Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups

Probabilistic cell-type assignment of single-cell RNA-seq for tumor micro-environment profiling

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes

Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses

Scalable whole-genome single-cell library preparation without pre-amplification

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor

ddClone: Joint Statistical Inference of Clonal Populations From Single Cell and Bulk Tumour Sequencing Data

Previous Next